Cressey T. R. auteur aut IRD Harrison L. auteur aut IRD Achalapong J. auteur aut IRD Kanjanavikai P. auteur aut IRD Ayudhaya O. P. N. auteur aut IRD Liampongsabuddhi P. auteur aut IRD Siriwachirachai T. auteur aut IRD Putiyanun C. auteur aut IRD Suriyachai P. auteur aut IRD Tierney C. auteur aut IRD Salvadori Nicolas auteur aut IRD Chinwong D. auteur aut IRD Decker Luc auteur aut IRD Tawon Y. auteur aut IRD Murphy T. V. auteur aut IRD Ngo-Giang-Huong Nicole auteur aut IRD Siberry G. K. auteur aut IRD Jourdain Gonzague auteur aut IRD iTAP Study Team auteur aut IRD text journalArticle eng text/pdf born digital access We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC(0-24) was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed. specialized pregnancy tenofovir hepatitis B virus pharmacokinetics THAILANDE 052 050 62 12 e01686-18 [5 p.] 2018 0066-4804 https://www.documentation.ird.fr/hor/fdi:010074806 10.1128/aac.01686-18 0066-4804 [F B010074806] https://www.documentation.ird.fr/hor/fdi:010074806 https://www.documentation.ird.fr/intranet/publi/2018/12/010074806.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2019-01-10 2019-01-11 fdi:010074806 fre